Insights - On Friday, the companies announced success in two phase 3 studies of the IL-4/IL-13 antibody in AD, and now plan to file for approval later this year with the FDA.
Read NowInsights - Acadia Pharmaceuticals' (ACAD) pimavanserin received a positive opinion from a panel of outside experts to the U.S. FDA on Tuesday, a final step before the regulatory body decides on the drug's approval in Parkinson's Disease Psychosis this May.
Read NowInsights - Portola used a unique study design in an attempt to enrich the trial and improve its odds of success. That might ultimately be betrixaban's undoing.
Read NowInsights - Shares of GW Pharmaceuticals (GWPH) doubled on Monday with the much-anticipated release of positive data from a phase 3 study of Epidiolex, the company’s proprietary formulation of … Continue Reading
Read NowInsights - Biotech had a Super Wednesday after Bernie Sanders’ not-so-super Tuesday.
Premium: Read NowInsights - From a $2 billion valuation to less than $300 million in five months, Chimerix (CMRX) (of Josh Hardy fame) is a standout among biotech stocks, for … Continue Reading
Read NowInsights - A bounce is underway since the NASDAQ Biotech Index Fund (IBB) tapped its 200-week moving average last week amid rare and significant oversold conditions (read more from last week).
Read Now
